Overview
I see patients with a broad range of movement disorders, including Parkinson's disease, tremors, ataxia, dystonia, tics, and Huntington's disease. I employ deep brain stimulation (DBS) therapy for selected patients with Parkinson's disease, tremor, or dystonia, and use botulinum toxin injections for certain patients with dystonia, tremors, or tics. I work with an interdisciplinary team of physicians, therapists, and other healthcare providers, with the overall goal of helping to improve the lives of patients with complex neurological diseases.
Current Appointments & Affiliations
Assistant Professor of Neurology
·
2021 - Present
Neurology, Movement Disorders,
Neurology
Recent Publications
Viewpoint on Milestones for Fellowship Training in Movement Disorders.
Journal Article Mov Disord · August 2022 Full text Open Access Link to item CiteInitial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S.
Journal Article Neurosurgery · July 1, 2022 BACKGROUND: Deep brain stimulation (DBS) is an effective therapy in advanced Parkinson disease (PD). Although both subthalamic nucleus (STN) and globus pallidus (GP) DBS show equivalent efficacy in PD, combined stimulation may demonstrate synergism. OBJECT ... Full text Open Access Link to item CiteTelemedicine and Deep brain stimulation - Current practices and recommendations.
Journal Article Parkinsonism Relat Disord · August 2021 The use of telemedicine in the management of chronic neurological conditions including movement disorders has expanded over time. In addition to enabling remote access to specialized care, telemedicine has also been shown to reduce caregiver burden and to ... Full text Link to item CiteRecent Grants
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY-STAGE PARKINSON'S DISEASE
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2025 - 2031Biohaven BHV-8000
Clinical TrialPrincipal Investigator · Awarded by Biohaven Pharmaceuticals · 2025 - 2028A Phase 2, Randomized, Double-Blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson's Disease
Clinical TrialPrincipal Investigator · Awarded by Asklepios BioPharmaceutical, Inc. · 2025 - 2028View All Grants
Education, Training & Certifications
University of North Carolina, Chapel Hill ·
2010
M.D.